OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products include OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepITóMAX, OMNIgeneóGut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company manufactures and sells oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, it provides medical devices used for the removal of benign skin lesions by cryosurgery or freezing; various immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physiciansí offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.